Coronavirus Infections
74
4
6
36
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.5%
7 terminated out of 74 trials
83.7%
-2.8% vs benchmark
15%
11 trials in Phase 3/4
25%
9 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (74)
Acute Respiratory Failure and COVID-19 in Real Life
In-depth Immunological Investigation of COVID-19.
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
NO Prevention of COVID-19 for Healthcare Providers
Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor
Humeral Shaft Fractures : Outcomes of Straight Percutaneous Intramedullary Nailing With Dynamic Distal Locking
Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)
Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine
Follow-up of Covid-19 Long Term Sequelae
French COVID Cohort
Study of the Incidence of SARS-CoV-2 Infection (COVID-19)
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
Butterfly - Clinical Performance Study
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil